Executive search firm Toft Group has placed Dr. Rachel Cervantes as Vice President of Business Development at Synthetic Genomics Inc., in La Jolla, CA. Dr. Cervantes was previously Vice President of Corporate Development at the University City Science Center in Philadelphia. She has over 20 years of experience in the commercial and scientific aspects of pharmaceutical innovation within large pharmaceutical, biotech, and academic research environments. She was Senior Director of Business Development at Egalet Corporation, and held similar roles at Inovio Pharmaceuticals and Merck & Co., where, in addition to evaluating, structuring and negotiating global healthcare partnerships, she also held leadership roles within R&D and marketing. In addition to her private sector experience, Dr. Cervantes was a research associate at the Salk Institute at Biological Sciences where she conducted NIH-funded cancer research. She holds a PhD in Cell & Molecular Biology from the University of Cincinnati, and an MBA from the University of Pennsylvania.
About Synthetic Genomics Inc.
Synthetic Genomics Inc. (SGI) is a global leader in the fields of synthetic biology and synthetic genomics utilizing our foundational intellectual property in these rapidly evolving disciplines to design and build biological systems to solve global sustainability challenges. SGI provides solutions in genomics research, bioproduction, and applied products. Their research segment is focused on genomics solutions for academic and commercial R&D organizations. The commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software. SGI’s efforts in bio-based production are targeted at improving existing biological production hosts and developing entirely new synthetic production hosts with the goal of more efficient production of pharmaceuticals, vaccines, nutritionals, and bio-industrial products derived from renewable biological resources. Their host systems can also enable entirely new products that were once not scientifically or economically viable.